About Amolyt Pharma
Amolyt Pharma is a company based in Ecully (France) founded in 2015 was acquired by Astrazeneca in March 2024.. Amolyt Pharma has raised $292.31 million across 3 funding rounds from investors including Crédit Agricole, Astrazeneca and EQT. Amolyt Pharma offers products and services including Enhertu and Pertuzumab. Amolyt Pharma operates in a competitive market with competitors including MBX Biosciences, OMass Therapeutics, Spruce, Spruce Biosciences and Sigilon, among others.
- Headquarter Ecully, France
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Amolyt Pharma, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$292.31 M (USD)
in 3 rounds
-
Latest Funding Round
$137.49 M (USD), Series C
Jan 06, 2023
-
Investors
Crédit Agricole
& 22 more
-
Employee Count
Employee Count
-
Acquired by
Astrazeneca
(Mar 14, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amolyt Pharma
Amolyt Pharma offers a comprehensive portfolio of products and services, including Enhertu and Pertuzumab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets HER2-positive metastatic breast cancer treatment
Used in combination for breast cancer progression control
Unlock access to complete
Funding Insights of Amolyt Pharma
Amolyt Pharma has successfully raised a total of $292.31M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $137.49 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $137.5M
-
First Round
First Round
(06 Aug 2019)
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2023 | Amount | Series C - Amolyt Pharma | Valuation | Sofinnova Partners , ICG | |
| Sep, 2021 | Amount | Series B - Amolyt Pharma | Valuation | Sectoral , Andera Partners | |
| Aug, 2019 | Amount | Series A - Amolyt Pharma | Valuation | Life Sciences Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Amolyt Pharma
Amolyt Pharma has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Crédit Agricole, Astrazeneca and EQT. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location | |
|
ICG is recognized as a global alternative asset manager.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in life sciences companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Amolyt Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Amolyt Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amolyt Pharma Comparisons
Competitors of Amolyt Pharma
Amolyt Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MBX Biosciences, OMass Therapeutics, Spruce, Spruce Biosciences and Sigilon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| domain | founded_year | HQ Location |
Spruce is engaged in providing real estate closing services.
|
|
| domain | founded_year | HQ Location |
Rare HPA axis diseases are targeted by Spruce Biosciences' therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for chronic diseases are developed via cell engineering platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amolyt Pharma
Frequently Asked Questions about Amolyt Pharma
When was Amolyt Pharma founded?
Amolyt Pharma was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Where is Amolyt Pharma located?
Amolyt Pharma is headquartered in Ecully, France. It is registered at Ecully, Auvergne-rhone-alpes, France.
Is Amolyt Pharma a funded company?
Amolyt Pharma is a funded company, having raised a total of $292.31M across 3 funding rounds to date. The company's 1st funding round was a Series A of $74.82M, raised on Aug 06, 2019.
What does Amolyt Pharma do?
Amolyt Pharma was established in 2015 in Ecully, France, within the biotechnology sector. Focus is placed on peptide-based therapeutics for rare endocrine and metabolic conditions. The pipeline includes eneboparatide, designed for hypoparathyroidism management, and AZP-3813, aimed at acromegaly treatment. Operations center on advancing these programs through research and development in the pharmaceutical field.
Who are the top competitors of Amolyt Pharma?
Amolyt Pharma's top competitors include MBX Biosciences, OMass Therapeutics and Spruce.
What products or services does Amolyt Pharma offer?
Amolyt Pharma offers Enhertu and Pertuzumab.
Who are Amolyt Pharma's investors?
Amolyt Pharma has 23 investors. Key investors include Crédit Agricole, Astrazeneca, EQT, Eurazeo, and Orbimed.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.